clinical trial · NCT06782932
Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·phase2·recruiting·n = 38
Pancreatic CancerAGEN2373BalstilimabCyclophosphamideGVAXAGEN2373 (RP2D)BalstilimabmKRASvax
brief summary
The purpose of this study is to determine the optimal dose of AGEN2373 that is safe when given in combination with balstilimab and Pancreatic GVAX Whole Cell Vaccine and evaluate the safety and clinical activity of balstilimab and AGEN2373 in combination with GVAX (Arm 1) or mKRASvax (Arm 2) in surgically resectable pancreatic adenocarcinoma.
started
May 27, 2025
primary completion
Dec 1, 2028
completion
Dec 1, 2028
last updated
Dec 3, 2025
official title
A Pilot Study Comparing Neoadjuvant and Adjuvant GVAX vs a Mutated KRAS Peptide Vaccine Given With Anti-PD-1 and Anti-CD137 for the Treatment of Surgically Resectable Pancreatic Adenocarcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol